Spirulina and atrial fibrillation: anticoagulant interactions, magnesium, and vascular mechanisms

AF pathophysiology

Atrial remodelling:AF begets AF — paroxysmal AF progressively causes atrial structural remodelling (fibrosis via TGF-β1), electrical remodelling (reduced refractory period via downregulation of L-type calcium channels), and autonomic remodelling. Oxidative stress is a key driver: NOX2 and NOX4 in atrial cardiomyocytes produce superoxide that activates NF-κB, driving inflammatory cytokine production (IL-6, IL-1β, TNF-α) that further promotes fibrosis.
Risk factors:Hypertension (most common modifiable risk), heart failure, coronary artery disease, obesity, sleep apnoea, diabetes. All share oxidative stress and inflammation as shared mechanisms — the same pathways phycocyanobilin inhibits.
Thromboembolic risk:AF causes atrial stasis, leading to thrombus formation in the left atrial appendage and stroke risk. Anticoagulation reduces stroke risk by 60–70%. CHA₂DS₂-VASc score determines treatment threshold.

Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X, protein C, S). INR therapeutic range for AF: 2.0–3.0. The INR window is narrow — small changes in vitamin K intake shift INR significantly.
Spirulina contains vitamin K1 (phylloquinone) at approximately 20–30 µg per 10 g serving. For comparison: 100 g spinach contains 483 µg; 100 g kale contains 817 µg. Spirulina’s vitamin K content is very low relative to green vegetables.
However, consistent daily intake of any vitamin K source can shift warfarin requirements. If starting spirulina on warfarin: maintain a consistent daily dose (do not vary), check INR 1–2 weeks after starting, and inform the anticoagulation clinic. The low absolute content means the INR shift is likely small — but it should be documented.
Do not use variable doses of spirulina on warfarin.INR stability requires consistent vitamin K intake. If taking spirulina, take the same dose every day at the same time.

Rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban, and dabigatran (Pradaxa) do not interact with vitamin K. Their mechanism is direct factor Xa inhibition (rivaroxaban, apixaban, edoxaban) or direct thrombin inhibition (dabigatran).
No documented pharmacokinetic interaction between spirulina compounds and DOACs. Rivaroxaban and apixaban are CYP3A4 substrates — spirulina compounds are not documented CYP3A4 inhibitors or inducers at food doses.
Spirulina’s mild antiplatelet effect (reducing TXA₂via GLA/DGLA/COX pathway) adds a modest antiplatelet component alongside anticoagulation. This is a theoretical additive bleeding risk — at spirulina doses (3–5 g), this is unlikely to be clinically significant, but patients with high bleeding risk should note it.

Some AF patients are on dual therapy (DOAC + aspirin, particularly after ACS or PCI). Spirulina’s antiplatelet contribution adds to the existing antiplatelet load. In patients already at elevated GI bleeding risk from dual therapy: discuss spirulina with cardiologist.

Spirulina contains approximately 80–120 mg magnesium per 10 g. Magnesium is essential for cardiac action potential generation — hypomagnesaemia is a recognised precipitant of AF and reduces the efficacy of antiarrhythmic drugs (flecainide, amiodarone).
Magnesium deficiency is common in AF patients on loop diuretics (furosemide causes renal magnesium wasting). Spirulina’s magnesium provides modest daily supplementation in this context — 8–12% of RDA per 10 g serving.

NOX2 inhibition in atrial cardiomyocytes reduces the superoxide-driven NF-κB activation that promotes atrial fibrosis. Animal models of AF show reduced atrial fibrosis with NOX2 inhibition. No clinical spirulina data in AF exists.
The anti-hypertensive and lipid-modulating effects of spirulina (reducing LDL, improving endothelial function) address AF risk factors rather than AF mechanism directly.

On warfarin: inform anticoagulation clinic, use a fixed consistent daily dose, check INR 2 weeks after starting, never vary the dose
On DOACs (rivaroxaban, apixaban, edoxaban, dabigatran): no vitamin K interaction; the mild antiplatelet addition is noted but unlikely to be clinically significant at 3–5 g/day
On dual antiplatelet + DOAC: discuss with cardiologist if on this combination given existing elevated bleeding risk
3–5 g/day; the cardiometabolic effects (lipid modulation, blood pressure, endothelial NO) address AF risk factors meaningfully
Magnesium in spirulina is particularly relevant if on loop diuretics; check serum magnesium if symptomatic arrhythmia persists